Is NCT05859490 recruiting in Portland, OR?

Yes, NCT05859490 is currently recruiting participants at its Portland, OR location. This yellow fever clinical trial is actively enrolling qualified participants.

How do I join the yellow fever clinical trial in Portland?

To join this clinical trial in Portland, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Portland clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Yellow Fever Clinical Trial in Portland, OR

About This Yellow Fever Study in Portland

The goal of this clinical trial is to assess the immune response to the yellow fever vaccine 17D in adults with prior 17D vaccination. The main questions this study aims to answer are: * how does prior vaccination affect antibody responses to re-vaccination? * how does prior vaccination affect the immune cell response to re-vaccination? Participants will: * have been previously vaccinated with 17D. * be re-vaccinated with 17D. * provide medical and travel histories. * provide a blood sample prior to vaccination * provide a blood sample approximately every other day for 14 days after vaccination. * provide a blood sample approximately 28 days after vaccination. * complete a daily diary of symptoms following vaccination for 14 days. * report any additional symptoms after 14 days.

Sponsor: Oregon Health and Science University

Who Can Participate

Inclusion Criteria

Aged ≥20 to \<50 years.

Male or female.

In good health at the time of screening as determined by medical history, physical examination, and clinical judgement of the investigator.

Documented history of Yellow fever vaccination 8 or more years prior. Documentation must be on a primary (not copied) vaccination card or a fully completed electronic medical record entry including date of administration and lot number administered.

Subjects who can comply with all trial procedures and are available for the duration of follow-up.

Exclusion Criteria

A clinically active infection or self-reported body temperature ≥38°C (100.4°F) within 3 days of scheduled date of vaccination (consider whether the finding is an exclusion criterion or criterion for delay of vaccination see Section 8.3).

A known hypersensitivity or allergy to any of the trial vaccine components including eggs.

Behavioral/cognitive impairment that, in the investigator's opinion, may interfere with the subject's ability to participate safely in the trial.

Any history of neurologic disorder, seizure disorder or neuro-inflammatory disease.

Any illness, or history of any illness that, in the investigator's opinion, could interfere with the trial or pose an additional risk to the subject during the trial period.

Known or suspected impairment/alteration of immune function, including:

Chronic use of oral steroids within 60 days prior to enrollment. Inhaled steroids are allowed.

Receipt of parenteral steroids within 60 days prior to screening visit.

Receipt of immunoglobulins and/or any blood products within the 3 months prior to enrollment or planned receipt during the trial.

Receipt of immunostimulants within 60 days prior to screening visit

Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months of enrollment.

Known Human Immunodeficiency Virus (HIV) infection or HIV-related disease.

Hepatitis C virus infection.

Genetic immunodeficiency.

History of splenic or thymic dysfunction.

Any serious chronic or progressive disease as assessed by the investigator (eg, neoplasm, hematologic malignancies, insulin dependent diabetes; cardiac, renal, or hepatic disease).

Body Mass Index (BMI) greater than or equal to 35 kg/m2.

Concurrent participation in any clinical trial with another investigational product 30 days prior to or during the conduct of this trial.

Vaccination within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment or plans to receive any vaccine within 28 days of trial vaccine administration (consider whether applicable as an exclusion criterion or criterion for delay of trial vaccine administration).

Use of antipyretics and/or analgesic medications within 24 hours prior to vaccination. Trial entry should be delayed to allow for a full 24-hours to have passed since last use of antipyretics and/or analgesic medications (consider whether applicable as an exclusion criterion or criterion for delay of trial vaccine administration).

Subjects with history of substance or alcohol abuse within the past 2 years.

Subjects who are pregnant or breastfeeding.

Subjects of childbearing potential who are sexually active with men and have not used "acceptable contraceptive methods" for at least 2 months prior to enrollment.

Of "childbearing potential" is defined as beyond onset of menarche and not: menopausal for 2 or more years, post bilateral tubal ligation at 1 year prior, post bilateral oophorectomy for at least 1 year or post hysterectomy.

"Acceptable birth control methods" include:

Hormonal contraceptives (such as oral, injection, transdermal patch, implant, cervical ring).

Barrier method (condom with spermicide or diaphragm with spermicide) every time during intercourse.

Intrauterine device.

Monogamous relationship with vasectomized partner (partner must have been vasectomized for at least 6 months prior to the subject's enrollment.

Subjects of childbearing potential who are sexually active with men and refuse acceptable contraceptive method up to 28 days after the vaccination.

Any positive or indeterminate pregnancy test.

Planned vaccination (during the trial conduct) against any other vaccine preventable disease.

Planned travel (during the trial) to any YFV endemic area.

Screening serology consistent with prior history of dengue, zika, West Nile or Japanese encephalitis virus infection. It may occur that a prospective subject meets all entry criteria except one that relates to short term clinical condition (e.g., fever, recent use of excluded medications). Under these circumstances, eligibility for delayed trial enrollment may be considered after inclusion/exclusion criteria have been rechecked, and if the subject is confirmed to be eligible.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Portland?

Yes, this clinical trial (NCT05859490) has an active research site in Portland, OR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Yellow Fever Treatment Options in Portland, OR

If you're searching for yellow fever treatment options in Portland, OR, this clinical trial (NCT05859490) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Portland research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced yellow fever specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all yellow fever clinical trials near you to find additional studies recruiting in your area.

Yellow Fever Clinical Trial in Portland, OR

Expert Care in Portland

IRB Approved

No-Cost Care

Apply for This Portland Location

Why Participate?

Simple Process